72 related articles for article (PubMed ID: 7853722)
21. Regulation of LDL receptors in vivo.
Bilheimer DW
Agents Actions Suppl; 1984; 16():191-203. PubMed ID: 6592957
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of lipid-lowering agents.
Sirtori CR; Manzoni C; Lovati MR
Cardiology; 1991; 78(3):226-35. PubMed ID: 1868500
[TBL] [Abstract][Full Text] [Related]
23. [Impact of lipid lowering therapy on liver function].
Paragh G; Fülöp P
Orv Hetil; 2009 Jun; 150(26):1205-12. PubMed ID: 19546077
[TBL] [Abstract][Full Text] [Related]
24. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells.
Banker DE; Mayer SJ; Li HY; Willman CL; Appelbaum FR; Zager RA
Blood; 2004 Sep; 104(6):1816-24. PubMed ID: 15161671
[TBL] [Abstract][Full Text] [Related]
25. Hyperlipoproteinemia in chronic renal failure: pathophysiological and therapeutic aspects.
Wanner C; Frommherz K; Hörl WH
Cardiology; 1991; 78(3):202-17. PubMed ID: 1868498
[TBL] [Abstract][Full Text] [Related]
26. [Hyperlipidemia in hemodialysis patients].
Nishikawa O; Mune M; Yukawa S
Nihon Rinsho; 2001 Mar; 59 Suppl 3():753-7. PubMed ID: 11347168
[No Abstract] [Full Text] [Related]
27. [Concept of hyperlipidemia and the clinical problems].
Yamamoto A
Nihon Naika Gakkai Zasshi; 1992 Nov; 81(11):1739-44. PubMed ID: 1479212
[No Abstract] [Full Text] [Related]
28. Lipid-lowering agents may fight cancer by denying it LDL.
Firestone RA
Int J Cancer; 2006 Nov; 119(10):2497. PubMed ID: 16858681
[No Abstract] [Full Text] [Related]
29. Lovastatin and other HMG-CoA reductase inhibitors.
Frishman WH; Zimetbaum P; Nadelmann J
J Clin Pharmacol; 1989 Nov; 29(11):975-82. PubMed ID: 2689473
[No Abstract] [Full Text] [Related]
30. Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma.
Matar P; Rozados VR; Binda MM; Roggero EA; Bonfil RD; Scharovsky OG
Clin Exp Metastasis; 1999 Feb; 17(1):19-25. PubMed ID: 10390143
[TBL] [Abstract][Full Text] [Related]
31. LDL-cholesterol lowering: to be or not to be too low.
Duprez D; Jacobs DR
Eur J Prev Cardiol; 2023 Sep; 30(12):1205-1206. PubMed ID: 37158485
[No Abstract] [Full Text] [Related]
32. Statin potency, LDL receptors and new onset diabetes.
Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
Curr Vasc Pharmacol; 2014; 12(5):739-40. PubMed ID: 25135802
[No Abstract] [Full Text] [Related]
33. Inhibition of the rate-limiting enzyme in cholesterol biosynthesis leads to up-regulation of the LDL receptor.
Nutr Rev; 1991 May; 49(5):153-6. PubMed ID: 2062464
[No Abstract] [Full Text] [Related]
34. Influence of anti-LDL receptor antibody on the transfer of cholesterol from LDL to isolated lymphocytes in normal subjects.
Iwata S; Sakuma N; Hibino T; Sato T; Yoneyama A; Kamiya Y; Kawaguchi M; Fujinami T; Kunimatsu M
Clin Biochem; 1995 Jun; 28(3):309-11. PubMed ID: 7554251
[No Abstract] [Full Text] [Related]
35. Are Cholesterol Treatment Targets a Deterrent to Optimal Lipid-Lowering Therapy?
Waters DD
JAMA Cardiol; 2017 Dec; 2(12):1392-1393. PubMed ID: 29117287
[No Abstract] [Full Text] [Related]
36. [Etiology of Secondary Hyperlipidemia and Abnormalities of Lipid Laboratory Tests -Chairmen's Introductory Remarks -].
Yoshida H; Miida T
Rinsho Byori; 2016 May; 64(5):506-507. PubMed ID: 30695358
[TBL] [Abstract][Full Text] [Related]
37. [Gene mutations responsible for hyperlipoproteinemia].
Sato R; Okabayashi M; Kajinami K
Nihon Rinsho; 2007 Jul; 65 Suppl 7():115-9. PubMed ID: 17824022
[No Abstract] [Full Text] [Related]
38. Foiling IDOL to Help Control Cholesterol.
Brown AJ; Hsieh J
Circ Res; 2016 Feb; 118(3):371-3. PubMed ID: 26846634
[No Abstract] [Full Text] [Related]
39. Parallels with nature.
Nelson A; Warriner S; Davey S
Nat Chem; 2014 Oct; 6(10):845-6. PubMed ID: 25242468
[No Abstract] [Full Text] [Related]
40. [Not Available].
Diener HC
MMW Fortschr Med; 2022 Oct; 164(18):28-29. PubMed ID: 36253685
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
